In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Management in Pharma: Insiderism

Executive Summary

Big Pharma is under the gun, with plenty of top management changes. By early next year, the industry will have seen five new CEOs; five new CFOs; a handful of changes in the top R&D spots, and a couple of new commercial bosses, all announced since the beginning of 2007 (an exhibit charts the changes). Of the sixteen job changes, six came about because the predecessor in the job was, if not outright fired, at least pressured to leave. But how much change are we really going to see?

You may also be interested in...



The Device Industry's Training Ground

Are successful medical device start-ups born or made? It's not clear, but Stanford University's Emerging Entrepreneur program is attempting to incorporate the experience of successful start-ups in a hnew learning program.

A Look Back at 2006: The Pipeline Challenge

Our review of top stories of 2006 touches on a variety of subjects, but the majority drive to one über-theme: the pipeline challenge. Products suddenly disappeared into the generic abyss, with nothing new to take their places. Compounds likely to succeed didn't. The price of in-licensable products soared. Even relatively good news for pipelines largely reflected the absence of further bad news: the safety squabbles did not result in higher hurdles to product approvals.

Pfizer's Change Management: Unfamiliar Faces

The dust at Pfizer still hasn't settled as new CEO Jeff Kindler shakes up the senior office suite at the world's largest pharmaceutical company. But the dust hasn't obscured the basic message: Pfizer's strategic and managerial model hasn't worked. What's more, the Big Pharma's board is one of a handful in the industry coming to similar conclusions.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel